Literature DB >> 12973748

Glutamate and the glutamate receptor system: a target for drug action.

Stefan Bleich1, Konstanze Römer, Jens Wiltfang, Johannes Kornhuber.   

Abstract

Glutamate is the most important excitatory neurotransmitter in the central nervous system. In the process, glutamate fulfills numerous physiological functions, but also plays an important role in the pathophysiology of different neurological and psychiatric diseases, especially when an imbalance in glutamatergic neurotransmission occurs. Under certain conditions, glutamate has a toxic action resulting from an activation of specific glutamate receptors, which leads to acute or chronic death of nerve cells. Such mechanisms are currently under discussion in acute neuronal death within the context of hypoxia, ischaemia and traumas, as well as in chronic neurodegenerative or neurometabolic diseases, idiopathic parkinsonian syndrome, Alzheimer's dementia and Huntington's disease. It is hoped that glutamate antagonists will lead to novel therapies for these diseases, whereby the further development of glutamate antagonists for blocking disease-specific subtypes of glutamate receptors may be of major importance in the future. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12973748     DOI: 10.1002/gps.933

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  35 in total

1.  Therapy for Alzheimer's Disease: How Effective are Current Treatments?

Authors:  Krista L Lanctôt; Ryan D Rajaram; Nathan Herrmann
Journal:  Ther Adv Neurol Disord       Date:  2009-05       Impact factor: 6.570

2.  Glutamate metabolizing enzymes in prefrontal cortex of Alzheimer's disease patients.

Authors:  Gulnur Sh Burbaeva; Irina S Boksha; Elena B Tereshkina; Olga K Savushkina; Lubov' I Starodubtseva; Marina S Turishcheva
Journal:  Neurochem Res       Date:  2005-11       Impact factor: 3.996

3.  Metabolic abnormalities in pain-processing regions of patients with fibromyalgia: a 3T MR spectroscopy study.

Authors:  P Feraco; A Bacci; Fab Pedrabissi; L Passamonti; G Zampogna; Fed Pedrabissi; N Malavolta; M Leonardi
Journal:  AJNR Am J Neuroradiol       Date:  2011-07-28       Impact factor: 3.825

4.  Vitamin C neuroprotection against dose-dependent glutamate-induced neurodegeneration in the postnatal brain.

Authors:  Shahid Ali Shah; Gwang Ho Yoon; Hyun-Ok Kim; Myeong Ok Kim
Journal:  Neurochem Res       Date:  2015-02-21       Impact factor: 3.996

Review 5.  Role of Glutamate and NMDA Receptors in Alzheimer's Disease.

Authors:  Rui Wang; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

6.  Neuroprotective effects of biochanin A against glutamate-induced cytotoxicity in PC12 cells via apoptosis inhibition.

Authors:  Ji Wei Tan; Chau Ling Tham; Daud A Israf; Sang Hyub Lee; Min Kyu Kim
Journal:  Neurochem Res       Date:  2012-12-06       Impact factor: 3.996

7.  Scrapie-induced defects in learning and memory of transgenic mice expressing anchorless prion protein are associated with alterations in the gamma aminobutyric acid-ergic pathway.

Authors:  Matthew J Trifilo; Manuel Sanchez-Alavez; Laura Solforosi; Joie Bernard-Trifilo; Stefan Kunz; Dorian McGavern; Michael B A Oldstone
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

8.  Protective effect of selaginellin on glutamate-induced cytotoxicity and apoptosis in differentiated PC12 cells.

Authors:  Chen-Jing Wang; Chang-Ping Hu; Kang-Ping Xu; Qiong Yuan; Fu-Shuang Li; Hui Zou; Gui-Shan Tan; Yuan-Jian Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-20       Impact factor: 3.000

9.  Network of brain protein level changes in glutaminase deficient fetal mice.

Authors:  Narkhyun Bae; Yvonne Wang; Lin Li; Stephen Rayport; Gert Lubec
Journal:  J Proteomics       Date:  2013-01-30       Impact factor: 4.044

Review 10.  Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease.

Authors:  Nazem Bassil; George T Grossberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.